Dr. Shannon Westin on PARP Inhibition for Ovarian Cancer

Published: Thursday July 20, 2017

Dr. Westin is a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic cancers. Her background in public health, with a focus on clinical investigation and epidemiology, has provided her with a clear understanding of the study design and validation techniques which are essential to the study of these topics. She is the principal investigator of several novel treatment trials for endometrial cancer as well as a Phase I trial of agents relevant to ovarian cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication